Predictors for coronary artery dilatation in Kawasaki disease

Main Article Content

Najib Advani
Anisa Rahmadhany
Sarah Rafika

Abstract

Background Kawasaki disease (KD) is an acute, self-limited, febrile illness of unknown cause that predominantly affects children below 5 years of age. It has a high incidence of coronary complications such as aneurysms. The current treatment of choice is intravenous immunoglobulin, which is costly, with aspirin. Identifying the predictive factors for coronary artery dilatation or aneurysm is important in order to establish the indications for giving immunoglobulin, especially when resources are limited.


Objective


To identify the predictors for the development of coronary artery dilatation in patients with Kawasaki disease


Methods This cross-sectional study was done between January 2003 and July 2013. Inclusion criteria were patients who fulfilled the American Heart Association criteria for acute Kawasaki disease, and had complete clinical, echocardiogram, and laboratory data [hemoglobin, leukocyte, platelet, albumin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR)]. All of them received immunoglobulin and aspirin.


Results Of 667 KD patients, 275 met the inclusion criteria. There were 185 (67%) males. Subjects’ ages varied between 1 to 157 months. The frequency of coronary artery dilatation at the acute phase was 33.3%. Multivariate analysis showed that >7-day duration of fever and hypoalbuminemia were significant predictive factors for coronary artery dilatation.


Conclusion Predictive factors for coronary artery dilatation are duration of fever over 7 days and hypoalbuminemia, while age, gender, hemoglobin level, leukocyte count, and platelet count are not. Frequency of coronary artery dilatation at the acute phase is 33.3%.

Article Details

How to Cite
1.
Advani N, Rahmadhany A, Rafika S. Predictors for coronary artery dilatation in Kawasaki disease. PI [Internet]. 17Oct.2018 [cited 22Nov.2018];58(5):257-2. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/1941
Section
Pediatric Cardiology

References

1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017:135:e927-99.
2. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379-85.
3. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998;81:1116-20.
4. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-9.
5. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-7.
6. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr. 1991;119:279-82.
7. Asai T. Evaluation method for degree of seriousness in Kawasaki disease. Acta Paediatr Jpn. 1983;25:170-85.
8. Nakano H. Prediction of patients with a high risk of coronary artery aneurysm in Kawasaki disease: indication for immunoglobulin therapy. Prog Clin Biol Res. 1987;250:287-97.
9. Harada K. Intravenous gamma globulin treatment in Kawasaki disease. Acta Paediatr Jpn. 1991;33:805-10.
10. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis
and therapy of Kawasaki disease in children. Circulation. 1993;87:1776-80.
11. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-71.
12. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneuryms. J Pediatr. 1986;108:388-92.
13. Daniels SR, Specker B, Capannari TE, Schwartz DC, Burke MJ, Kaplan S. Correlates of coronary artery aneurysm formation in patients with Kawasaki disease. Am J Dis Child. 1987;141:205-7.
14. Ichida F, Fatica NS, O’Loughlin JE, Klein AA, Snyder MS, Levin AR, et al. Epidemiologic aspects of Kawasaki disease in a Manhattan hospital. Pediatrics. 1989;84:235-41.
15. Kim T, Choi W, Woo CW, Choi B, Lee J, Lee K, et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr. 2007;166:421-5.
16. Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol. 2003;24:122-6.
17. Belay ED, Maddox RA, Holman RC, Curns AT, Ballah K, Schonberger LB. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. Pediatr Infec Dis J. 2006;25:245-9.
18. McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007;116:174-9.
19. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassifed as normal in Kawasaki disease. J Pediatr. 1998;133:254-8.
20. Fukazawa R, Ogawa S. Long-term prognosis of patients with Kawasaki disease: at risk for future atherosclerosis? J Nippon Med Sch. 2009;76:124-33.
21. Advani N, Satroasmoro S, Ontoseno T. Uiterwaal CS. Long-term outcome of coronary artery dilatation in Kawasaki disease. Ann Pediatr Card. 2018;11:125-9.
22. Ishihara H, Izumida N, Hosaki J. Criterion for early prediction of coronary artery involvement by clinical manifestations in patients with Kawasaki disease. Bull Tokyo Med Dent Univ. 1985;32:77-89.
23. Yasukawa K, Terai M, Shulman ST, Toyozaki, Yajima S, Kohno Y, et al. Systematic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation. 22;105:766-9.
24. Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y. Prognostic impact of vascular leakage in acute Kawasaki disease. Circulation. 2003;108:325-30.
25. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533-44.